Skip to main content
JUBILANT PHARMOVA LIMITED logo

JUBILANT PHARMOVA LIMITED — Investor Relations & Filings

Ticker · JUBLPHARMA ISIN · INE700A01033 LEI · 335800C6LDKWF4HQH833 BSE.NS Manufacturing
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2023-05-30 Board/Management Inform…
Country IN India
Listing BSE.NS JUBLPHARMA

About JUBILANT PHARMOVA LIMITED

https://www.jubilantpharmova.com/

Jubilant Pharmova Limited is an integrated global pharmaceutical company operating through three primary segments: Pharmaceuticals, Contract Research and Development Services (CRDS), and Proprietary Novel Drugs. The Pharmaceuticals segment specializes in radiopharmaceuticals for nuclear medicine, allergy immunotherapy, and the development and manufacturing of generic formulations. It also provides Contract Development and Manufacturing Organization (CDMO) services for sterile injectables and non-sterile products. The CRDS division offers comprehensive drug discovery and development solutions to biopharmaceutical companies worldwide. Furthermore, the Proprietary Novel Drugs segment focuses on creating innovative therapies for oncology and autoimmune diseases. The company leverages its advanced manufacturing infrastructure and research capabilities to serve global markets with a focus on complex chemistry and specialized healthcare solutions.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding changes in the company's board of directors and key managerial personnel. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure of material events including board changes. The content details resignations and appointments of directors and key executives, including dates and brief profiles. There is no financial data, earnings information, or report publication mentioned. The document is not a report itself but an announcement of management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length (11,005 characters) supports it being a detailed announcement rather than a brief notice or report publication announcement.
2023-05-30 English
Change in Director(s)
Board/Management Information Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding changes in the company's board of directors and key managerial personnel. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure of material events including changes in management. The content details resignations and appointments of directors and key executives, including dates and brief profiles. There is no financial data, earnings information, or report publication mentioned. The document is not a report itself but an announcement of management changes. Therefore, it fits the category of Board/Management Information (MANG). The document length (11,005 characters) supports it being a detailed announcement rather than a brief notice or certification. Hence, the classification is MANG with high confidence.
2023-05-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 95% confidence The document is a detailed presentation dated May 30, 2023, addressed to stock exchanges and investors, containing extensive financial data for Q4 and full fiscal year ended March 31, 2023. It includes segment-wise revenue splits, business structure, operational highlights, and detailed financial results with tables and charts. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal annual report or earnings release. The presence of forward-looking statements and detailed business segment analysis further supports this classification. The document is not a brief earnings release, regulatory filing, or announcement but a comprehensive presentation for investors.
2023-05-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is a press release dated May 29, 2023, from Jubilant Pharmova Limited, announcing an update regarding a USFDA inspection classification of their Contract Manufacturing facility in Montreal, Canada. It is addressed to stock exchanges and references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events. The content is an announcement of a regulatory inspection outcome and the company's response, not a financial report, earnings release, or detailed management discussion. The document is relatively short (4541 characters) and serves as a communication to the market rather than a detailed report or transcript. It does not contain financial statements, voting results, or management changes. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance disclosures that do not fit other specific categories.
2023-05-29 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a compliance disclosure under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed related party transactions for the half year ended March 31, 2023. The content is a regulatory compliance filing providing detailed transactional data rather than a full financial report or management discussion. It is not an annual or interim report, earnings release, or audit report. It is a regulatory announcement of related party transactions as required by stock exchange regulations. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-05-29 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated May 29, 2023, announcing the financial results for the quarter and fiscal year ended March 31, 2023, for Jubilant Pharmova Limited. It includes detailed financial data such as revenue, EBITDA, profit before tax, and segment-wise financial highlights. The document is not a full annual report but rather an initial announcement of quarterly and annual financial results. It is not a transcript, management report, or regulatory filing. The presence of key financial metrics and the announcement nature aligns with an Earnings Release (ER). The document length is about 15,000 characters, which is typical for a detailed earnings release. Therefore, the appropriate classification is Earnings Release (ER).
2023-05-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.